ICD-10 Code Z86.000: Personal History of In-Situ Neoplasm of Breast – Complete Coding & Billing Guide

What Does ICD-10 Code Z86.000 Mean?

ICD-10 code Z86.000 is a billable, valid diagnosis code that documents a patient’s personal history of in-situ neoplasm of the breast — specifically, a prior diagnosis of in-situ carcinoma (classifiable to D05) that has been treated and is no longer active. The code belongs to Chapter 21 of ICD-10-CM (Factors Influencing Health Status and Contact with Health Services) and signals to payers that the breast neoplasm is a historical condition, not a current illness.

Key attributes of this code:

• Valid and billable for fiscal year 2026 (effective October 1, 2025)
• Classified under the inclusion terms: Conditions classifiable to D05 (e.g., ductal carcinoma in situ, DCIS; lobular carcinoma in situ, LCIS)
• Exempt from Present on Admission (POA) reporting for inpatient admissions
• Unacceptable as a principal diagnosis — it must be paired with a primary reason for the encounter
• Outpatient Default CCSR: Yes — valid as first-listed diagnosis in outpatient settings when it drives the encounter

What Conditions and Diagnoses Does Z86.000 Cover?

Z86.000 applies when a patient has a documented, treated history of any in-situ carcinoma of the breast, and there is no current evidence of active disease. The underlying in-situ condition must have been classifiable to the D05 category at the time of original diagnosis.

Clinical presentations and scenarios this code captures include:

• Prior diagnosis and treatment of ductal carcinoma in situ (DCIS)
• Prior diagnosis and treatment of lobular carcinoma in situ (LCIS)
• History of intracystic carcinoma in situ of the breast (when previously coded under D05)
• Status post lumpectomy, mastectomy, or radiation for confirmed in-situ breast neoplasm, with no current evidence of disease
• Surveillance encounters (follow-up mammography, clinical breast exam) following completion of in-situ breast neoplasm treatment

What Does Z86.000 Specifically Exclude?

The ICD-10-CM Tabular contains an Excludes2 note at the Z86.0 category level, meaning these conditions are not captured by Z86.000 and may be coded concurrently if appropriate:

• Personal history of malignant neoplasms (Z85.-) — use Z85.3 if the patient had an invasive breast malignancy, not an in-situ lesion
• Active in-situ neoplasm — if the patient currently has DCIS (D05.x), do not use Z86.000; use the active D05.x code
• Personal history of benign neoplasm (Z86.01-) — a benign breast mass is a separate historical category

When Is Z86.000 the Right Code to Use?

Correct application of Z86.000 depends on confirming that the in-situ neoplasm is genuinely resolved and that the encounter is driven by history or surveillance — not active management of a current diagnosis. In practice, coders frequently encounter Z86.000 in surveillance mammography, follow-up oncology visits, and primary care annual wellness encounters where the past DCIS or LCIS is a relevant background condition influencing current care decisions.

Follow these steps to confirm correct code selection:

1. Verify the original pathology. Confirm the patient’s prior breast neoplasm was classified as in-situ (D05.x), not invasive (C50.x). This determination must come from pathology documentation — not a radiologic impression alone.
2. Confirm treatment is complete. The in-situ lesion must have been excised, treated, or otherwise eradicated. If treatment (surgery, radiation) is still ongoing for the breast site, use the active D05.x code, not a history code.
3. Confirm no active disease. The provider’s documentation must state — explicitly or by clear implication — that there is no current evidence of recurrence or residual in-situ neoplasm at the breast site.
4. Identify the primary reason for the encounter. Because Z86.000 cannot stand as a principal diagnosis in inpatient settings and is unacceptable as the sole reason for a claim, you must assign the primary encounter code first (e.g., Z09 follow-up, Z12.31 screening mammogram) and attach Z86.000 as a secondary, supporting code.
5. Apply the “code first” instruction. Per ICD-10-CM Official Coding Guidelines, any follow-up examination after treatment should be coded first using Z09 (follow-up after completed treatment for other conditions), with Z86.000 as an additional code.

How Does Z86.000 Differ From Z85.3 and D05.x?

This is the most common point of confusion for coders and billers working with breast neoplasm histories.

In practice, auditors flag Z85.3 used in place of Z86.000 as a specificity error. Coders who see “history of breast cancer” in the chart without reviewing the original pathology type run the highest risk of selecting the wrong history code.

What Documentation Is Required to Support Z86.000?

Z86.000 is a circumstance-influencing health status code — it doesn’t describe a current illness, but it must still be clinically supported by clear documentation. Payers expect auditable evidence that the history is accurately characterized as in-situ and fully resolved.

What Must the Provider Document in the Clinical Notes?

A compliant clinical note should include:

1. Explicit reference to prior in-situ breast diagnosis — language such as “history of DCIS,” “s/p excision of lobular carcinoma in situ,” or “prior in-situ carcinoma of the breast, treated”
2. Original pathology confirmation — ideally, a notation (or reference to prior records) confirming the lesion was in-situ (D05-classifiable), not invasive
3. Treatment completion statement — documentation that surgery, radiation, or other directed treatment is finished and no further active treatment is ongoing
4. No evidence of recurrence — a statement such as “no evidence of disease,” “imaging negative,” or “NED” to confirm the code reflects true historical status
5. Reason for current encounter — the clinical note must support a separately coded primary reason for the visit (surveillance mammogram, follow-up exam, wellness encounter), since Z86.000 cannot drive the encounter alone

What Is the Documentation Standard for Inpatient vs. Outpatient Settings?

How Does Z86.000 Affect Medical Billing and Claims?

Z86.000 is most often submitted as a secondary diagnosis on outpatient claims, where it provides clinical context for surveillance services. Understanding its billing behavior prevents claim rejections and inappropriate medical necessity denials.

Key payer and billing considerations:

• Z86.000 cannot be the sole or principal diagnosis on a CMS-1500 claim — it must accompany a primary encounter code
• When paired with Z12.31 (screening mammogram) or Z09 (follow-up after treatment), Z86.000 supports medical necessity for surveillance imaging covered under Medicare preventive benefits
• Medicare and most commercial payers accept Z86.000 as a secondary code supporting enhanced surveillance mammography frequency beyond routine annual screening
• Some payers require Z86.000 to be present on claims for high-risk breast MRI (CPT 77048/77049) to support coverage under high-risk screening protocols
• Do not include the decimal point when submitting claims electronically — submit as Z86000, not Z86.000, to avoid clearinghouse rejection

What CPT or Procedure Codes Are Commonly Billed With Z86.000?

Are There Prior Authorization or Coverage Restrictions?

• Medicare covers screening mammography (CPT 77067) annually for women 40+ regardless of history codes, but Z86.000 supports medical necessity for more frequent diagnostic imaging beyond routine thresholds
• Commercial payers vary on high-risk breast MRI coverage — Z86.000 alone may not satisfy all payer-specific criteria; verify applicable Local Coverage Determination (LCD) or payer policy before billing
• Some payers distinguish between “high-risk” and “personal history” categories — confirm whether Z86.000 or a risk assessment code is required to trigger enhanced surveillance coverage
• Prior authorization may be required for breast MRI when Z86.000 is the supporting diagnosis; check payer policy before ordering

What Coding Errors Should You Avoid With Z86.000?

Mistakes with Z86.000 cluster around three core misunderstandings: confusing history type, ignoring sequencing rules, and applying the code when the condition is still active. These errors generate both claim denials and compliance exposure.

1. Using Z85.3 instead of Z86.000 for prior DCIS/LCIS. Z85.3 is reserved for malignant neoplasm history. Applying it to a purely in-situ history misrepresents the original diagnosis severity and creates a specificity error.
2. Using Z86.000 when active D05.x applies. If the patient still has an active in-situ diagnosis under treatment, Z86.000 is incorrect. Use D05.x until treatment is fully complete and no residual disease is documented.
3. Listing Z86.000 as the principal or first-listed diagnosis in inpatient settings. The MCE will flag this as an unacceptable principal diagnosis, resulting in a claim edit or rejection.
4. Omitting the Z09 follow-up code. Per ICD-10-CM Official Coding Guidelines (Section I.C.21), follow-up examination after completed treatment must be coded first with Z09 when the encounter is surveillance-based. Skipping Z09 misrepresents the encounter purpose.
5. Relying on the provider’s “history of breast cancer” language without pathology review. That phrase could indicate malignant history (Z85.3) or in-situ history (Z86.000). Coders must review or query for the original histology before assigning.

What Do Auditors Look for When Reviewing Claims With Z86.000?

• Pathology documentation confirming in-situ classification (D05 category) at original diagnosis — auditors expect this to be accessible in the record
• Z86.000 coded as principal diagnosis on inpatient claims — an automatic flag in Medicare Code Editor (MCE) review
• Absence of Z09 on surveillance follow-up claims — suggests the follow-up coding convention was not applied
• Concurrent active D05.x and Z86.000 on the same claim — logically inconsistent; cannot have both an active and historical in-situ code simultaneously
• Z85.3 and Z86.000 together without clinical justification — use only one history code unless the patient had two separate, distinct breast neoplasm events (invasive and in-situ at different times)

How Does Z86.000 Relate to Other ICD-10 Codes?

Z86.000 sits within a web of related codes used across the breast neoplasm coding pathway. Understanding where it fits prevents both under-coding (losing clinical context) and over-coding (misrepresenting diagnosis severity).

What Is the Correct Code Sequencing When Z86.000 Appears With Other Diagnoses?

1. Follow-up encounter after in-situ breast treatment: Sequence Z09 first, then Z86.000 as additional code.
2. Screening mammography encounter with prior DCIS history: Sequence Z12.31 first (the encounter purpose), then Z86.000 as supporting context.
3. Annual wellness visit where prior DCIS history is documented: Sequence the wellness code (Z00.00 or Z00.01) first; Z86.000 is a secondary code reflecting relevant history.
4. Inpatient admission unrelated to breast history: Sequence the condition driving the admission first; Z86.000 may be listed as a secondary code if it is clinically relevant to the current care episode.

Real-World Coding Scenario — How Z86.000 Is Applied in Practice

Patient encounter: A 54-year-old female presents to her oncologist for a 12-month surveillance visit. She was diagnosed with DCIS of the right breast (D05.12) three years ago, underwent lumpectomy with clear margins, completed radiation therapy, and has had no evidence of recurrence. Today’s visit includes clinical breast exam and an order for a bilateral diagnostic mammogram. The provider notes “history of right breast DCIS, treated, NED.”

Correct Code Application

• Z09 — Encounter for follow-up examination after completed treatment for other conditions (sequenced first — this is the encounter purpose)
• Z86.000 — Personal history of in-situ neoplasm of breast (supporting code — documents the treated DCIS history)
• Z12.39 or 77066 — Diagnostic mammogram ordered as part of the surveillance plan (procedure code on imaging claim)

Rationale: Treatment is complete, documentation confirms no active disease, and the encounter is surveillance-based. Z09 appropriately drives the encounter; Z86.000 provides the clinical context supporting the surveillance frequency.

Common Mistake in This Scenario

• Incorrect code assigned: D05.12 (active DCIS, right breast)
• Why it fails: D05.12 is appropriate only while the in-situ lesion is under active evaluation or treatment. Applying it three years post-treatment with documented NED misrepresents the patient’s current condition as active disease, inflates diagnostic severity, and risks a compliance finding on audit.

Frequently Asked Questions About ICD-10 Code Z86.000

Is ICD-10 Code Z86.000 Valid for Use in 2026?

Z86.000 is a valid, billable ICD-10-CM code for fiscal year 2026, effective October 1, 2025, with no changes to its description, validity, or inclusion terms in the current code year. Coders should confirm annually against the CMS ICD-10-CM code updates released each spring to verify no revisions have been applied before the October 1 effective date.

What Is the Difference Between Z86.000 and Z85.3?

Z86.000 applies when a patient’s prior breast neoplasm was an in-situ carcinoma (classifiable to D05, such as DCIS or LCIS), while Z85.3 applies when the prior breast neoplasm was an invasive malignancy (classifiable to C50). These codes are mutually exclusive at the category level — the ICD-10-CM Official Coding Guidelines explicitly exclude personal history of carcinoma-in-situ (Z86.00-) from the Z85 malignant history category.

Can Z86.000 Be the Only Diagnosis Code on a Claim?

Z86.000 can be the first-listed diagnosis on outpatient claims in limited circumstances — for example, a dedicated surveillance visit where the history code drives the encounter purpose. However, it is unacceptable as a principal diagnosis on inpatient claims, and on most outpatient encounters it should be paired with a primary encounter code such as Z09 or Z12.31 to fully represent the reason for the visit.

When Should Z09 Be Coded With Z86.000?

Z09 should be coded as the primary diagnosis whenever the encounter’s sole purpose is follow-up surveillance after completed in-situ breast neoplasm treatment. Per the ICD-10-CM Official Coding Guidelines (Section I.C.21), follow-up codes should be listed first and history codes added to provide complete clinical context. If during follow-up a recurrence is discovered, replace both Z09 and Z86.000 with the appropriate active diagnosis code.

Does a Prior DCIS History Affect Coverage for Screening Mammography?

Yes, documented personal history of in-situ breast neoplasm (Z86.000) commonly supports medical necessity for enhanced surveillance mammography frequency beyond standard annual screening intervals. Under Medicare, screening mammography (CPT 77067) is covered annually; however, Z86.000 alongside a diagnostic indication may support coverage for additional views or a shift to diagnostic mammography billing. Commercial payer policies vary — always verify the applicable Local Coverage Determination (LCD) or payer benefit language.

Can Z86.000 and Z85.3 Both Appear on the Same Claim?

Using both Z86.000 and Z85.3 on the same claim is clinically valid only if the patient has two separate, distinct breast neoplasm histories — for example, a prior DCIS in the left breast and a prior invasive carcinoma in the right breast at different points in time. Both codes cannot describe the same lesion. Auditors will flag concurrent use of both codes without documentation supporting two distinct neoplasm events.

Key Takeaways

Every coder working with breast neoplasm histories should remember these core rules for Z86.000:

• Z86.000 documents history of in-situ breast neoplasm only — if the original lesion was invasive, Z85.3 applies instead
• The code is billable but not acceptable as a principal diagnosis in inpatient settings and must be paired with a primary encounter code in most outpatient encounters
• Z09 must be sequenced first when the visit is a post-treatment surveillance follow-up
• Only assign Z86.000 when treatment is confirmed complete and no active disease is documented
• Always review original pathology — provider language of “breast cancer history” alone is insufficient to assign this code without confirming the in-situ vs. invasive distinction
• The code is POA-exempt for inpatient admissions, so no POA indicator is required
• For the 2026 fiscal year, there have been no changes to Z86.000’s description, validity, or inclusion terms — verify each October for future annual updates via CMS ICD-10-CM code tables

For authoritative coding guidance, refer to the CMS ICD-10-CM Official Guidelines for Coding and Reporting, the AHA Coding Clinic for ICD-10-CM, and the WHO ICD-10 reference classification. For breast-specific DCIS clinical context, the CDC’s cancer surveillance resources provide population-level data supporting documentation standards.